Scolaris Content Display Scolaris Content Display

Vitamin D supplementation for prevention of mortality in adults

This is not the most recent version

view the current version 10 January 2014

Appendices

Appendix 1. Search strategy

Search terms

Part I: Vitamin D
1 exp Vitamin D/
2 exp Cholecalciferol/
3 exp ergocalciferols/ or exp dihydrotachysterol/ or exp 25‐hydroxyvitamin d 2/
4 exp Hydroxycholecalciferols/
5 vitamin D?.tw,ot.
6 (cholecalciferol$ or calcifediol$ or calcitriol$ or dihydrotachysterol$ or hydroxyvitamin$
d?).tw,ot.
7 (alfacalcidol$ or alphacalcidol$ or colecalciferol$).tw,ot.
8 or/1‐7

Part II: Mortality
9 exp Mortality/
10 mortality.tw,ot.
11 mortaliti$.tw,ot.
12 or/9‐11

Part III: Prevention
13 exp Primary Prevention/
14 (prevention$ or prevent$).tw,ot.
15 exp Neoplasm/
16 (cancer$ or neoplasm$ or tumo?r$).tw,ot.
17 or/13‐16

Part IV: RCT's/CCT's
18 exp Randomized Controlled Trials as topic/
19 Randomized Controlled Trial.pt.
20 exp Controlled Clinical Trials as topic/
21 Controlled Clinical Trial.pt.
22 exp Random Allocation/
23 exp Double‐Blind Method/
24 exp Single‐Blind Method/
25 or/18‐24

Part V: Meta‐analysis, reviews and HTA
26 exp "Review Literature as topic"/
27 exp Technology Assessment, Biomedical/
28 exp Meta‐analysis as topic/
29 Meta‐analysis.pt.
30 hta.tw,ot.
31 (health technology adj6 assessment$).tw,ot.
32 (meta analy$ or metaanaly$ or meta?analy$).tw,ot.
33 ((review$ or search$) adj10 (literature$ or medical database$ or medline or pubmed or
embase or chochrane or cinhal or psychinfo or psychlit or healthstar or biosis or current
content$ or systemat$)).tw,ot.
34 or/26‐33

Part VI: IV + V
35 25 or 34

Part VI: I AND III AND VI
36 8 and 17 and 35
37 limit 36 to animals
38 limit 36 to humans
39 37 not 38
40 36 not 39

Part VII: I AND II AND VI
41 8 and 12 and 35
42 limit 41 to animals
43 limit 41 to humans
44 42 not 43
45 41 not 44

Part VIII: VI + VII
46 40 or 45

Appendix 2. Baseline characteristics

Characteristic

study ID1

study ID2

study ID3

study ID4

study ID5

study ID6

study ID7

study ID8

study ID9

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1: vitamin D

C1: placebo

Sex [female% / male%]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Age [mean years (SD)]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Ethnic groups [%]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Duration of disease [mean years (SD)]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Notes

Appendix 3. Adverse events

Characteristic

study ID1

study ID12

study ID3

study ID4

study ID5

study ID6

study ID7

study ID8

study ID9

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1: vitamin D

C1: placebo

Participants who died [n]

I1: n/N

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Adverse events [n]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Adverse events [%]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Serious adverse events [n]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Serious adverse events [%]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Drop‐outs due to adverse events [n]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Drop‐outs due to adverse events [%]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Hospitalisation [n]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Hospitalisation [%]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Out‐patient treatment [n]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Out‐patient treatment [%]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Symptoms [n]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Symptoms [%]

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

Table 1. Study populations

study ID

intervention

[n] screened

[n] randomised

[n] safety

[n] ITT

[n] finishing study

comments

ID1

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

ID2

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

ID3

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

ID3

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

ID4

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

ID5

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

ID6

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

ID7

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

ID8

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

ID9

Intervention 1 (I1)

Intervention 2 (I2)

Control 1 (C1)

Control 2 (C2)

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

I1:

I2:

C1:

C2:

Total:

ITT = intention‐to‐treat
Figures and Tables -
Table 1. Study populations
Navigate to table in Protocol